Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold

Article Related Press Releases (1) Related Articles (3) Stock Quotes (1) Comments (0)

Canaccord Genuity downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold with a price target of $25 on of Allergan takeover.

"We’re still surprised by the timing though more may be known when filings come out. At this point we think the deal price is reasonable and for MAPP shareholders it eliminates FDA risk assuming a pre-PDUFA closing (April 15) and in our view for AGN
makes another bidder unlikely."

For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.

Shares of MAP Pharmaceuticals closed at $24.71 yesterday, with a 52 week range of $11.11-$24.77.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
• Macquarie Downgrades CME Group (CME) to Neutral
• Goldman Sachs Downgrades InterXion Holding (INXN) to Neutral

Create E-mail Alert Related Categories

Downgrades

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?